<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SIMPONI ARIA- golimumab solution </strong><br>Janssen Biotech, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use SIMPONI ARIA<span class="Sup">®</span> safely and effectively.  See full prescribing information for SIMPONI ARIA. <br><br>SIMPONI ARIA <br>(golimumab) injection, for intravenous use <br>Initial U.S. Approval: 2009</div>
<div class="Warning">
<div>
<h1 class="Warning">WARNING:  SERIOUS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span> AND MALIGNANCY</h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul>
<li><span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> leading to hospitalization or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> including <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> (TB), <span class="product-label-link" type="condition" conceptid="4000938" conceptname="Bacterial sepsis">bacterial sepsis</span>, invasive fungal (such as <span class="product-label-link" type="condition" conceptid="433134" conceptname="Histoplasmosis">histoplasmosis</span>), and other <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> have occurred in patients receiving SIMPONI ARIA (<a href="#S5.1">5.1</a>).</span></li>
<li><span class="Bold">Discontinue SIMPONI ARIA if a patient develops a serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> (<a href="#S5.1">5.1</a>).</span></li>
<li><span class="Bold">Perform test for latent TB; if positive, start treatment for TB prior to starting SIMPONI ARIA (<a href="#S5.1">5.1</a>).</span></li>
<li><span class="Bold">Monitor all patients for active TB during treatment, even if initial latent TB test is negative (<a href="#S5.1">5.1</a>).</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which SIMPONI ARIA is a member (<a href="#S5.2">5.2</a>).</span></li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="100%">
<col align="left" valign="top" width="75%">
<col align="right" valign="top" width="25%">
<tbody class="Headless"><tr>
<td align="left">Warnings and Precautions (<a href="#s5.1">5.1</a>, <a href="#S5.2">5.2</a>,<a href="#s5.9"> 5.9</a>)</td>
<td align="right">12/2014</td>
</tr></tbody>
</table></div>
</div>
<div></div>
<div class="Warning">
<div>
<h1 class="Warning">WARNING:  SERIOUS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span> AND MALIGNANCY</h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul>
<li><span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> leading to hospitalization or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> including <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> (TB), <span class="product-label-link" type="condition" conceptid="4000938" conceptname="Bacterial sepsis">bacterial sepsis</span>, invasive fungal (such as <span class="product-label-link" type="condition" conceptid="433134" conceptname="Histoplasmosis">histoplasmosis</span>), and other <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> have occurred in patients receiving SIMPONI ARIA (<a href="#S5.1">5.1</a>).</span></li>
<li><span class="Bold">Discontinue SIMPONI ARIA if a patient develops a serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> (<a href="#S5.1">5.1</a>).</span></li>
<li><span class="Bold">Perform test for latent TB; if positive, start treatment for TB prior to starting SIMPONI ARIA (<a href="#S5.1">5.1</a>).</span></li>
<li><span class="Bold">Monitor all patients for active TB during treatment, even if initial latent TB test is negative (<a href="#S5.1">5.1</a>).</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which SIMPONI ARIA is a member (<a href="#S5.2">5.2</a>).</span></li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">SIMPONI ARIA is a <span class="product-label-link" type="condition" conceptid="4147451" conceptname="Tumor necrosis">tumor necrosis</span> factor (TNF) blocker indicated for the treatment of adult patients with moderately to severely active <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span> (RA) in combination with methotrexate (<a href="#S1.1">1.1</a>) </p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>2 mg/kg intravenous infusion over 30 minutes at weeks 0 and 4, then every 8 weeks (<a href="#S2.1">2.1</a>)</li>
<li>Dilution of supplied SIMPONI ARIA solution with 0.9% w/v sodium chloride is required prior to administration (<a href="#S2.3">2.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Injection:  50 mg/4 mL (12.5 mg/mL) in a single use vial (<a href="#S3">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc"><li>None (<a href="#S4">4</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> – Do not start SIMPONI ARIA during an active <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.  If an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> develops, monitor carefully, and stop SIMPONI ARIA if <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> becomes serious (<a href="#S5.1">5.1</a>).</li>
<li>Invasive <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> – For patients who develop a systemic illness on SIMPONI ARIA, consider empiric antifungal therapy for those who reside in or travel to regions where mycoses are endemic (<a href="#S5.1">5.1</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="4281232" conceptname="Type B viral hepatitis">Hepatitis B reactivation</span> – Monitor HBV carriers during and several months after therapy.  If reactivation occurs, stop SIMPONI ARIA and begin anti-viral therapy (<a href="#S5.1">5.1</a>).</li>
<li> Malignancies – More cases of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> have been observed among patients receiving TNF-blockers compared with patients in the control groups.  Cases of other malignancies have been observed among patients receiving TNF-blockers (<a href="#S5.2">5.2</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span> – Worsening, or new onset, may occur.  Stop SIMPONI ARIA if new or worsening symptoms occur (<a href="#S5.3">5.3</a>).</li>
<li>Demyelinating disease, exacerbation or new onset, may occur (<a href="#S5.4">5.4</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>: Serious systemic <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> may occur (<a href="#S5.10">5.10</a>).</li>
</ul></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence ≥3%) are: <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (<a href="#S6.1">6.1</a>). </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact <br> Janssen Biotech, Inc. at 1-800-JANSSEN (1-800-526-7736) or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch.</span></span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Biologics, including abatacept and anakinra: Increased risk of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (<a href="#S5.1">5.1</a>, <a href="#S5.5">5.5</a>, <a href="#S5.6">5.6</a>, <a href="#S5.7">5.7</a>, <a href="#S7.2">7.2</a>)</li>
<li>Live vaccines should not be given with SIMPONI ARIA (<a href="#S5.9">5.9</a>, <a href="#S7.3">7.3</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 8/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING: SERIOUS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span> AND MALIGNANCY</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1    <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1    <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2   Evaluation for <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span> and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B Prior to Dosage</a></h2>
<h2><a href="#section-2.3" class="toc">2.3   Important Administration Instructions</a></h2>
<h1><a href="#section-3" class="toc">3	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1   Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Malignancies</a></h2>
<h2><a href="#section-5.3" class="toc">5.3   <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4   Demyelinating Disorders</a></h2>
<h2><a href="#section-5.5" class="toc">5.5   Use with Abatacept</a></h2>
<h2><a href="#section-5.6" class="toc">5.6   Use with Anakinra</a></h2>
<h2><a href="#section-5.7" class="toc">5.7   Switching Between Biological Disease Modifying Antirheumatic Drugs (DMARDs)</a></h2>
<h2><a href="#section-5.8" class="toc">5.8   Hematologic <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">Cytopenias</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9   Vaccinations/Therapeutic Infectious Agents</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2   Post-marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1    Methotrexate</a></h2>
<h2><a href="#section-7.2" class="toc">7.2   Biologic Products for RA</a></h2>
<h2><a href="#section-7.3" class="toc">7.3   Live Vaccines/Therapeutic Infectious Agents</a></h2>
<h2><a href="#section-7.4" class="toc">7.4   Cytochrome P450 Substrates</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13	NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING: SERIOUS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span> AND MALIGNANCY</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
<p class="First"><span class="Bold">SERIOUS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span></span></p>
<p><span class="Bold">Patients treated with SIMPONI ARIA are at increased risk for developing serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that may lead to hospitalization or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.  Most patients who developed these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were taking concomitant immunosuppressants such as methotrexate or corticosteroids.</span></p>
<p><span class="Bold">Discontinue SIMPONI ARIA if a patient develops a serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</span></p>
<p><span class="Bold">Reported <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> with TNF-blockers, of which SIMPONI ARIA is a member, include:</span></p>
<ul>
<li><span class="Bold">Active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>, including reactivation of latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>. Patients with <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> have frequently presented with disseminated or extrapulmonary disease. Test patients for latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> before SIMPONI ARIA use and during therapy. Initiate treatment for latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> prior to SIMPONI ARIA use.</span></li>
<li><span class="Bold">Invasive <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>, including <span class="product-label-link" type="condition" conceptid="433134" conceptname="Histoplasmosis">histoplasmosis</span>, <span class="product-label-link" type="condition" conceptid="437217" conceptname="Coccidioidomycosis">coccidioidomycosis</span>, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span>, <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">aspergillosis</span>, <span class="product-label-link" type="condition" conceptid="433146" conceptname="Blastomycosis">blastomycosis</span> and <span class="product-label-link" type="condition" conceptid="438350" conceptname="Pneumocystosis">pneumocystosis</span>. Patients with <span class="product-label-link" type="condition" conceptid="433134" conceptname="Histoplasmosis">histoplasmosis</span> or other invasive <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> may present with disseminated, rather than localized, disease. Antigen and antibody testing for <span class="product-label-link" type="condition" conceptid="433134" conceptname="Histoplasmosis">histoplasmosis</span> may be negative in some patients with active <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Consider empiric anti-fungal therapy in patients at risk for invasive <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> who develop severe systemic illness.</span></li>
<li><span class="Bold">Bacterial, viral, and other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to opportunistic pathogens, including Legionella and Listeria.</span></li>
</ul>
<p><span class="Bold">Consider the risks and benefits of treatment with SIMPONI ARIA prior to initiating therapy in patients with chronic or recurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</span></p>
<p><span class="Bold">Monitor patients closely for the development of signs and symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> during and after treatment with SIMPONI ARIA, including the possible development of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> in patients who tested negative for latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> prior to initiating therapy <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.2"></a><p></p>
<p class="First"><span class="Bold">MALIGNANCY</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which SIMPONI ARIA is a member <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1    <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span></h2>
<p class="First">SIMPONI ARIA, in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1    <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span></h2>
<p class="First">The SIMPONI ARIA dosage regimen is 2 mg per kg given as an intravenous infusion over 30 minutes at weeks 0 and 4, then every 8 weeks thereafter.</p>
<p>SIMPONI ARIA should be given in combination with methotrexate. Other non-biologic DMARDs, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or analgesics may be continued during treatment with SIMPONI ARIA.</p>
<p>The efficacy and safety of switching between intravenous and subcutaneous formulations and routes of administration have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2   Evaluation for <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span> and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B Prior to Dosage</h2>
<p class="First">Prior to initiating SIMPONI ARIA and periodically during therapy, evaluate patients for active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> and test for latent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>. Prior to initiating SIMPONI ARIA, test patients for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span> <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3   Important Administration Instructions</h2>
<p class="First">SIMPONI ARIA solution for intravenous infusion should be diluted by a healthcare professional using aseptic technique as follows:</p>
<ol>
<li>Calculate the dosage and the number of SIMPONI ARIA vials needed based on the recommended dosage of 2 mg/kg and the patient's weight.   Each 4 mL vial of SIMPONI ARIA contains 50 mg of golimumab.</li>
<li>Check that the solution in each vial is colorless to light yellow. The solution may develop a few fine translucent particles, as golimumab is a protein. Do not use if opaque particles, discoloration or other foreign particles are present.</li>
<li>Dilute the total volume of the SIMPONI ARIA solution with 0.9% w/v sodium chloride for infusion to a final volume of 100 mL. For example, this can be accomplished by withdrawing a volume of the 0.9% w/v sodium chloride solution from the 100-mL infusion bag or bottle equal to the total volume of SIMPONI ARIA. Slowly add the total volume of SIMPONI ARIA solution to the 100-mL infusion bag or bottle. Gently mix. Discard any unused solution remaining in the vials.</li>
<li>Prior to infusion, visually inspect the diluted SIMPONI ARIA solution for particulate matter or discoloration. Do not use if these exist.</li>
<li>Use only an infusion set with an in-line, sterile, non-pyrogenic, low protein-binding filter (pore size 0.22 micrometer or less).</li>
<li>Do not infuse SIMPONI ARIA concomitantly in the same intravenous line with other agents. No physical biochemical compatibility studies have been conducted to evaluate the use of SIMPONI ARIA with other intravenous agents in the same intravenous line.</li>
<li>Infuse the diluted solution over 30 minutes.</li>
<li>Once diluted, the infusion solution can be stored for 4 hours at room temperature.</li>
</ol>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3	DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Injection:  50 mg of golimumab per 4 mL of solution (12.5 mg of golimumab per mL) in each single-use vial.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1   Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Patients treated with SIMPONI ARIA are at increased risk for developing serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> involving various organ systems and sites that may lead to hospitalization or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">Opportunistic infections</span> due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">aspergillosis</span>, <span class="product-label-link" type="condition" conceptid="433146" conceptname="Blastomycosis">blastomycosis</span>, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span>, <span class="product-label-link" type="condition" conceptid="437217" conceptname="Coccidioidomycosis">coccidioidomycosis</span>, <span class="product-label-link" type="condition" conceptid="433134" conceptname="Histoplasmosis">histoplasmosis</span>, legionellosis, <span class="product-label-link" type="condition" conceptid="438059" conceptname="Listeriosis">listeriosis</span>, <span class="product-label-link" type="condition" conceptid="438350" conceptname="Pneumocystosis">pneumocystosis</span>, and <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> have been reported with TNF-blockers. Patients have frequently presented with disseminated rather than localized disease. The concomitant use of a TNF-blocker and abatacept or anakinra was associated with a higher risk of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>; therefore, the concomitant use of SIMPONI ARIA and these biologic products is not recommended <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5</a>, <a href="#S5.6">5.6</a>) and <a href="#S7.2">Drug Interactions (7.2)</a>]</span>.</p>
<p>Treatment with SIMPONI ARIA should not be initiated in patients with an active <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including clinically important <span class="product-label-link" type="condition" conceptid="4018050" conceptname="Localized infection">localized infections</span>. Patients greater than 65 years of age, patients with co-morbid conditions and/or patients taking concomitant immunosuppressants such as corticosteroids or methotrexate may be at greater risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Consider the risks and benefits of treatment prior to initiating SIMPONI ARIA in patients:</p>
<ul>
<li>with chronic or recurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>;</li>
<li>who have been exposed to <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>;</li>
<li>with a history of an <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infection</span>;</li>
<li>who have resided or traveled in areas of endemic <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> or endemic mycoses, such as <span class="product-label-link" type="condition" conceptid="433134" conceptname="Histoplasmosis">histoplasmosis</span>, <span class="product-label-link" type="condition" conceptid="437217" conceptname="Coccidioidomycosis">coccidioidomycosis</span>, or <span class="product-label-link" type="condition" conceptid="433146" conceptname="Blastomycosis">blastomycosis</span>; or</li>
<li>with underlying conditions that may predispose them to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.1"></a><p></p>
<p class="First"><span class="Bold Italics">Monitoring</span></p>
<p>Closely monitor patients for the development of signs and symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> during and after treatment with SIMPONI ARIA. Discontinue SIMPONI ARIA if a patient develops a serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, an <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infection</span>, or <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>. For patients who develop a new <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> during treatment with SIMPONI ARIA, perform a prompt and complete diagnostic workup appropriate for an immunocompromised patient and initiate appropriate antimicrobial therapy and closely monitor them.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.2"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span></span></p>
<p>Cases of reactivation of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> or new <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> have been observed in patients receiving TNF-blockers, including patients who have previously received treatment for latent or active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>. Evaluate patients for <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> risk factors and test for latent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> prior to initiating SIMPONI ARIA and periodically during therapy.</p>
<p>Treatment of latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> prior to therapy with TNF-blockers has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> reactivation during therapy. Prior to initiating SIMPONI ARIA, assess if treatment for latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> is needed; An <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> of 5 mm or greater is a positive tuberculin skin test, even for patients previously vaccinated with Bacille Calmette-Guerin (BCG).</p>
<p>Consider anti-<span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> therapy prior to initiation of SIMPONI ARIA in patients with a past history of latent or active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> but having risk factors for <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Consultation with a physician with expertise in the treatment of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> is recommended to aid in the decision whether initiating anti-<span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> therapy is appropriate for an individual patient.</p>
<p style="border-left:1px solid;"><span class="XmChange">Cases of active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> have occurred in patients treated with the subcutaneous formulation of golimumab during and after treatment for latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>. Monitor patients for the development of signs and symptoms of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> including patients who tested negative for latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> prior to initiating therapy, patients who are on treatment for latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>, or patients who were previously treated for <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</span></p>
<p>Consider <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> in the differential diagnosis in patients who develop a new <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> during SIMPONI ARIA treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>, or who have had close contact with a person with active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.3"></a><p></p>
<p class="First"><span class="Bold Italics">Invasive <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal Infections</span></span></p>
<p>If patients develop a serious systemic illness and they reside or travel in regions where mycoses are endemic, consider invasive <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span> in the differential diagnosis. Consider appropriate empiric antifungal therapy and take into account both the risk for severe <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span> and the risks of antifungal therapy while a diagnostic workup is being performed. Antigen and antibody testing for <span class="product-label-link" type="condition" conceptid="433134" conceptname="Histoplasmosis">histoplasmosis</span> may be negative in some patients with active <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. To aid in the management of such patients, consider consultation with a physician with expertise in the diagnosis and treatment of invasive <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.4"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B Virus Reactivation</span></p>
<p>The use of TNF-blockers, of which SIMPONI ARIA is a member, has been associated with reactivation of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) in patients who are <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B carriers (i.e., surface antigen positive). In some instances, HBV reactivation occurring in conjunction with TNF-blocker therapy has been fatal. The majority of these reports have occurred in patients who received concomitant immunosuppressants.</p>
<p>All patients should be tested for HBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> before initiating TNF-blocker therapy. For patients who test positive for <span class="product-label-link" type="condition" conceptid="4318957" conceptname="Hepatitis B surface antigen">hepatitis B surface antigen</span>, consultation with a physician with expertise in the treatment of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B is recommended before initiating TNF-blocker therapy. The risks and benefits of treatment should be considered prior to prescribing TNF-blockers, including SIMPONI ARIA, to patients who are carriers of HBV. Adequate data are not available on whether anti-viral therapy can reduce the risk of HBV reactivation in HBV carriers who are treated with TNF-blockers. Patients who are carriers of HBV and require treatment with TNF-blockers should be closely monitored for clinical and laboratory signs of active HBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> throughout therapy and for several months following termination of therapy.</p>
<p>In patients who develop HBV reactivation, TNF-blockers should be stopped and antiviral therapy with appropriate supportive treatment should be initiated. The safety of resuming TNF-blockers after HBV reactivation has been controlled is not known. Therefore, prescribers should exercise caution when considering resumption of TNF-blockers in this situation and monitor patients closely.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Malignancies</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2.1"></a><p></p>
<p class="First"><span class="Bold Italics">Malignancies in Pediatric Patients</span></p>
<p>Malignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with TNF-blocking agents (initiation of therapy ≤ 18 years of age), of which SIMPONI ARIA is a member. Approximately half the cases were <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span>, including Hodgkin's and non-Hodgkin's <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>. The other cases represented a variety of malignancies, including rare malignancies that are usually associated with <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>, and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months (range 1 to 84 months) after the first dose of TNF-blocker therapy. Most of the patients were receiving concomitant immunosuppressants. These cases were reported post-marketing and are derived from a variety of sources, including registries and spontaneous post-marketing reports.  Use of SIMPONI ARIA in patients under 18 years of age has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2.2"></a><p></p>
<p class="First"><span class="Bold Italics">Malignancies in Adult Patients</span></p>
<p>The risks and benefits of TNF-blocker treatment including SIMPONI ARIA should be considered prior to initiating therapy in patients with a known malignancy other than a successfully treated non-<span class="product-label-link" type="condition" conceptid="4049499" conceptname="Malignant melanoma">melanoma skin</span> cancer (NMSC) or when considering continuing a TNF-blocker in patients who develop a malignancy.</p>
<p>In the controlled portions of clinical trials of TNF-blockers including the subcutaneous formulation of golimumab more cases of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> have been observed among patients receiving anti-TNF treatment compared with patients in the control groups. Patients with RA and other chronic inflammatory diseases, particularly patients with highly active disease and/or chronic exposure to immunosuppressant therapies, may be at higher risk (up to several fold) than the general population for the development of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, even in the absence of TNF-blocking therapy. Cases of acute and <span class="product-label-link" type="condition" conceptid="140057" conceptname="Chronic leukemia">chronic leukemia</span> have been reported with post-marketing TNF-blocker use in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> and other indications. Even in the absence of TNF-blocker therapy, patients with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> may be at a higher risk (approximately 2-fold) than the general population for the development of <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>.</p>
<p style="border-left:1px solid;"><span class="XmChange">Rare post-marketing cases of hepatosplenic T-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> (HSTCL) have been reported in patients treated with TNF-blocking agents. This rare type of T-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> has a very aggressive disease course and is usually fatal. Nearly all of the reported TNF-blocker associated cases have occurred in patients with Crohn's disease or <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>. The majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine (AZA) or 6-mercaptopurine (6–MP) concomitantly with a TNF-blocker at or prior to diagnosis. A risk for the development for hepatosplenic T-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> in patients treated with TNF-blockers cannot be excluded.</span></p>
<p>Melanoma has been reported in patients treated with TNF-blocking agents, including the subcutaneous formulation of golimumab. <span class="product-label-link" type="condition" conceptid="4100425" conceptname="Merkel cell carcinoma">Merkel cell carcinoma</span> has been reported in patients treated with TNF-blocking agents. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.</p>
<p>In controlled trials of other TNF-blockers in patients at higher risk for malignancies (e.g., patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>, patients with Wegener's granulomatosis treated with concomitant cyclophosphamide) a greater portion of malignancies occurred in the TNF-blocker group compared to the controlled group. In an exploratory clinical trial evaluating the use of the subcutaneous formulation of golimumab in patients with severe persistent <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, more patients treated with golimumab reported malignancies compared with control patients. The significance of this finding is unknown.</p>
<p>During the controlled portion of the Phase 3 trial in RA for SIMPONI ARIA, the incidence of malignancies other than <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> and NMSC per 100-patient-years of follow-up was 0.56 (95% CI: 0.01, 3.11) in the SIMPONI ARIA group compared with an incidence of 0 (95% CI: 0.00, 3.79) in the placebo group. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3   <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span></h2>
<p class="First">Cases of worsening <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (CHF) and new onset CHF have been reported with TNF-blockers, including SIMPONI ARIA. In several exploratory trials of other TNF-blockers in the treatment of CHF, there were greater proportions of TNF-blocker treated patients who had CHF exacerbations requiring hospitalization or increased mortality. SIMPONI ARIA has not been studied in patients with a history of CHF and SIMPONI ARIA should be used with caution in patients with CHF. If a decision is made to administer SIMPONI ARIA to RA patients with CHF, these patients should be closely monitored during therapy, and SIMPONI ARIA should be discontinued if new or worsening symptoms of CHF appear.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4   Demyelinating Disorders</h2>
<p class="First">Use of TNF-blockers, of which SIMPONI ARIA is a member, has been associated with rare cases of new onset or exacerbation of central nervous system (CNS) demyelinating disorders, including <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> (MS) and peripheral demyelinating disorders, including Guillain-Barré syndrome. Cases of central <span class="product-label-link" type="condition" conceptid="4139599" conceptname="Demyelination">demyelination</span>, MS, <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span>, and peripheral <span class="product-label-link" type="condition" conceptid="4050856" conceptname="Peripheral demyelinating neuropathy">demyelinating polyneuropathy</span> have rarely been reported in patients treated with the subcutaneous formulation of golimumab. Prescribers should exercise caution in considering the use of TNF-blockers, including SIMPONI ARIA, in patients with central or peripheral nervous system demyelinating disorders. Discontinuation of SIMPONI ARIA should be considered if these disorders develop.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5   Use with Abatacept</h2>
<p class="First">In controlled trials, the concurrent administration of another TNF-blocker and abatacept was associated with a greater proportion of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> than the use of a TNF-blocker alone; and the combination therapy, compared to the use of a TNF-blocker alone, has not demonstrated improved clinical benefit in the treatment of RA. Therefore, the combination of TNF-blockers including SIMPONI ARIA and abatacept is not recommended <span class="Italics">[see <a href="#S7.2">Drug Interactions (7.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6   Use with Anakinra</h2>
<p class="First">Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocker, was associated with a greater portion of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and no additional benefits compared with the TNF-blocker alone. Therefore, the combination of anakinra with TNF-blockers, including SIMPONI ARIA, is not recommended <span class="Italics">[see <a href="#S7.2">Drug Interactions (7.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7   Switching Between Biological Disease Modifying Antirheumatic Drugs (DMARDs)</h2>
<p class="First">Care should be taken when switching from one biologic product to another biologic product since overlapping biological activity may further increase the risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8   Hematologic <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">Cytopenias</span></h2>
<p class="First">There have been post-marketing reports of <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> in patients receiving TNF-blockers. In clinical studies, cases of <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> have also occurred in SIMPONI ARIA-treated patients. Caution should be exercised when using TNF-blockers, including SIMPONI ARIA, in patients who have or have had significant <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9   Vaccinations/Therapeutic Infectious Agents</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.9.1"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Italics">Live Vaccines</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">Patients treated with SIMPONI ARIA may receive vaccinations, except for live vaccines. In patients receiving anti-TNF therapy, limited data are available on the response to live vaccination, or on the secondary transmission of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> by live vaccines. Use of live vaccines could result in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including disseminated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.9.2"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Italics">Therapeutic Infectious Agents</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">Other uses of therapeutic infectious agents such as live attenuated bacteria (e.g., BCG bladder instillation for the treatment of cancer) could result in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including disseminated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. It is recommended that therapeutic infectious agents not be given concurrently with SIMPONI ARIA.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.10"></a><a name="section-5.10"></a><p></p>
<h2>5.10 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">In post-marketing experience, serious systemic <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>) have been reported following administration of the subcutaneous formulation of golimumab. Some of these reactions occurred after the first administration of golimumab. If an anaphylactic or other serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> occurs, administration of SIMPONI ARIA should be discontinued immediately and appropriate therapy instituted.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The most serious adverse reactions were:</p>
<ul>
<li>Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>
</li>
<li>Malignancies <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>The safety data described below are based on one, randomized, double-blind, controlled Phase 3 trial in patients with RA receiving SIMPONI ARIA by intravenous infusion (Trial 1). The protocol included provisions for patients taking placebo to receive treatment with SIMPONI ARIA at Week 16 or Week 24 either by patient response (based on uncontrolled disease activity) or by design, so that adverse events cannot always be unambiguously attributed to a given treatment. Comparisons between placebo and SIMPONI ARIA were based on the first 24 weeks of exposure.</p>
<p>Trial 1 included 197 control-treated patients and 463 SIMPONI ARIA-treated patients (which includes control-treated patients who switched to SIMPONI ARIA at Week 16). The proportion of patients who discontinued treatment due to adverse reactions in the controlled phase of Trial 1 through Week 24 was 3.5% for SIMPONI ARIA-treated patients and 0.5% for placebo-treated patients. <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span> was the most common adverse reaction reported in the trial through Week 24 occurring in 6.5% of SIMPONI ARIA-treated patients as compared with 7.6% of control-treated patients, respectively.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></p>
<p>Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> observed in SIMPONI ARIA-treated patients included <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>, <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> (TB), and invasive <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>. Cases of TB included pulmonary and extrapulmonary TB. The majority of the TB cases occurred in countries with a high incidence rate of TB <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
<p>In the controlled phase of Trial 1 through Week 24, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were observed in 27% of SIMPONI ARIA-treated patients compared with 24% of control-treated patients, and serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were observed in 0.9% of SIMPONI ARIA-treated patients and 0.0% of control-treated patients. Through Week 24, the incidence of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> per 100 patient-years of follow-up was 2.2 (95% CI 0.61, 5.71) for the SIMPONI ARIA group, and 0 (0.00, 3.79) for the placebo group. In the controlled and uncontrolled portions of Trial 1, 958 total patient-years of follow-up with a median follow-up of approximately 92 weeks, the incidence per 100 patient-years of all serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> was  4.07 (CI: 2.90, 5.57) in patients receiving SIMPONI ARIA <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>. In the controlled and uncontrolled portions of Trial 1, in SIMPONI ARIA treated patients, the incidence of active TB per 100 patient-years was 0.31 (95% CI: 0.06; 0.92) and the incidence of other <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> per 100 patient-years was 0.42 (95% CI: 0.11, 1.07).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Bold Italics">Malignancies</span></p>
<p>One case of malignancy other than <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> and NMSC with SIMPONI ARIA was reported through Week 24 during the controlled phase of Trial 1. In the controlled and uncontrolled portions through approximately 92 weeks, the incidence of malignancies per 100 patient-years, other than <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> and NMSC, in SIMPONI ARIA-treated patients was 0.31 (CI: 0.06, 0.92)  and the incidence of NMSC was 0.1 (95% CI: 0.00, 0.58).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Bold Italics">Liver Enzyme Elevations</span></p>
<p>There have been reports of severe hepatic reactions including <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span> in patients receiving TNF-blockers.</p>
<p>In the controlled phase of Trial 1, through Week 24, ALT elevations ≥ 5 × ULN occurred in 0.8% of SIMPONI ARIA-treated patients and 0% of control-treated patients and ALT elevations ≥ 3 × ULN occurred in 2.3% of SIMPONI ARIA-treated patients and 2.5% of control-treated patients.</p>
<p>Since many of the patients in the Phase 3 trial were also taking medications that cause liver enzyme elevations (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs], methotrexate [MTX], or isoniazid prophylaxis), the relationship between SIMPONI ARIA and liver enzyme elevation is not clear.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.4"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">Autoimmune Disorders</span> and Autoantibodies</span></p>
<p>The use of TNF-blockers, of which SIMPONI ARIA is a member, has been associated with the formation of autoantibodies and, rarely, with the development of a lupus-like syndrome.</p>
<p>At Week 20 in Trial 1, 17% of SIMPONI ARIA-treated patients and 13% of control patients were newly ANA-positive (at titers of 1:160 or greater). Of these patients, one SIMPONI ARIA-treated patient and no control-treated patients had newly positive anti-dsDNA antibodies.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.5"></a><p></p>
<p class="First"><span class="Bold Italics">Administration Reactions</span></p>
<p>In the controlled phase of Trial 1 through Week 24, 1.1% of SIMPONI ARIA infusions were associated with an infusion reaction compared with 0.2% of infusions in the control group. The most common infusion reaction in SIMPONI ARIA treated patients was <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. No serious infusion reactions were reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.6"></a><p></p>
<p class="First"><span class="Bold Italics">Immunogenicity</span></p>
<p>Antibodies to SIMPONI ARIA were detected in 13 (3%) golimumab-treated patients following IV administration of SIMPONI ARIA in combination with MTX through Week 24 of Trial 1.</p>
<p>All patients who were positive for antibodies to golimumab had neutralizing antibodies based on an in vitro cell-based assay. The small number of patients positive for antibodies to SIMPONI ARIA limits the ability to draw definitive conclusions regarding the relationship between antibodies to golimumab and clinical efficacy or safety measures.</p>
<p>The data above reflect the percentage of patients whose test results were considered positive for antibodies to SIMPONI ARIA in an ELISA assay. The ELISA assay is subject to interference by co-present golimumab and thus the results are an underestimate of the rate of product immunogenicity and are in addition highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors including sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to SIMPONI ARIA with the incidence of antibodies to other products may be misleading.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.7"></a><p></p>
<p class="First"><span class="Bold Italics">Other Adverse Reactions</span></p>
<p>Table 1 summarizes the adverse drug reactions that occurred at a rate of at least 1% in the SIMPONI ARIA + MTX group with a higher incidence than in the placebo + MTX group during the controlled period of Trial 1 through Week 24.</p>
<a name="table1"></a><table width="85%">
<caption><span>Table 1:	Adverse Drug Reactions Reported by ≥ 1% of SIMPONI ARIA-Treated Patients and with a Higher Incidence than Placebo-Treated Patients in Trial 1 through Week 24</span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th align="left"></th>
<th class="Botrule" align="center">Placebo + MTX</th>
<th class="Botrule" align="center">SIMPONI ARIA + MTX</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left">Patients treated</td>
<td align="center">197</td>
<td align="center">463</td>
</tr>
<tr><td align="left" colspan="3">Adverse Reaction</td></tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span> (such as <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span>, and <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>)</td>
<td align="center">12%</td>
<td align="center">13%</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral infections</span> (such as <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span> and herpes)</td>
<td align="center">3%</td>
<td align="center">4%</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">Bacterial infections</span></td>
<td align="center">0%</td>
<td align="center">1%</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></td>
<td align="center">1%</td>
<td align="center">3%</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td align="center">2%</td>
<td align="center">3%</td>
</tr>
<tr>
<td align="left"><span class="Bold">Skin and subcutaneous disorders</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="center">1%</td>
<td align="center">3%</td>
</tr>
<tr>
<td align="left"><span class="Bold">General disorders and administration site conditions</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td align="center">1%</td>
<td align="center">2%</td>
</tr>
<tr>
<td align="left"><span class="Bold">Blood and lymphatic disorders</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr class="Last">
<td align="left">   <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></td>
<td align="center">0%</td>
<td align="center">1%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.8"></a><p></p>
<p class="First"><span class="Bold Italics">Other and less common clinical trial adverse drug reactions</span></p>
<p>Adverse drug reactions that do not appear in Table 1 or that occurred &lt;1% in SIMPONI ARIA-treated patients during Trial 1 through Week 24 that do not appear in the Warnings and Precautions section included the following events listed by system organ class:</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span>: Superficial <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">lower respiratory tract infection</span> (<span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>), <span class="product-label-link" type="condition" conceptid="198199" conceptname="Pyelonephritis">pyelonephritis</span></p>
<p><span class="Italics">Investigations</span>: <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">Alanine aminotransferase</span> increased, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> increased, neutrophil count decreased</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span>: <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2   Post-marketing Experience</h2>
<p class="First">There is no post-marketing experience available for SIMPONI ARIA.  The following adverse reactions have been identified during post-approval use of the subcutaneous formulation of golimumab. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to golimumab exposure.</p>
<p><span class="Italics">Neoplasm Benign and Malignant</span>:  Melanoma <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span></span>: Serious systemic <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>) <span class="Italics">[see <a href="#S5.10">Warnings and Precautions (5.10)</a>]</span>, <span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span></p>
<p><span class="Italics">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial lung disease</span></p>
<p><span class="Italics">Skin and subcutaneous tissue disorders</span>: <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">Skin exfoliation</span>, bullous <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1    Methotrexate</h2>
<p class="First">SIMPONI ARIA should be used with methotrexate (MTX) <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span>. Following IV administration, concomitant administration of methotrexate decreases the clearance of SIMPONI ARIA by approximately 9% based on population PK analysis. In addition, concomitant administration of methotrexate decreases the SIMPONI ARIA clearance by reducing the development of anti-golimumab antibodies.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2   Biologic Products for RA</h2>
<p class="First">An increased risk of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> has been seen in clinical RA studies of other TNF-blockers used in combination with anakinra or abatacept, with no added benefit; therefore, use of SIMPONI ARIA with other biologic products, including abatacept or anakinra is not recommended <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5</a> and <a href="#S5.6">5.6</a>)]</span>. A higher rate of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> has also been observed in RA patients treated with rituximab who received subsequent treatment with a TNF-blocker. The concomitant use of SIMPONI ARIA with biologics approved to treat RA is not recommended because of the possibility of an increased risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3   Live Vaccines/Therapeutic Infectious Agents</h2>
<p class="First">Live vaccines should not be given concurrently with SIMPONI ARIA <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>]</span>.</p>
<p>Therapeutic infectious agents should not be given concurrently with SIMPONI ARIA <span class="Italics">[see <a href="#s5.9">Warnings and Precautions (5.9)</a>]</span>.</p>
<p>Infants born to women treated with SIMPONI ARIA during their pregnancy may be at increased risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> for up to 6 months. Administration of live vaccines to infants exposed to SIMPONI ARIA <span class="Italics">in utero</span> is not recommended for 6 months following the mother's last SIMPONI ARIA infusion during pregnancy <span class="Italics">[see <a href="#S8.1">Use in Specific Populations (8.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4   Cytochrome P450 Substrates</h2>
<p class="First">The formation of CYP450 enzymes may be suppressed by increased levels of cytokines (e.g., TNFα) during chronic <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. Therefore, it is expected that for a molecule that antagonizes cytokine activity, such as golimumab, the formation of CYP450 enzymes could be normalized. Upon initiation or discontinuation of SIMPONI ARIA in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Category B – There are no adequate and well-controlled studies of SIMPONI ARIA in pregnant women. Because animal reproduction and developmental studies are not always predictive of human response, it is not known whether SIMPONI ARIA can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. SIMPONI ARIA should be used during pregnancy only if clearly needed.</p>
<p>An embryofetal developmental toxicology study was performed in which pregnant cynomolgus monkeys were treated subcutaneously with golimumab during the first trimester with doses up to 50 mg/kg twice weekly (200 times greater than the maximum recommended human dose-MRHD) and has revealed no evidence of harm to maternal animals or fetuses. Umbilical cord blood samples collected at the end of the second trimester showed that fetuses were exposed to golimumab during gestation. In this study, <span class="Italics">in utero</span> exposure to golimumab produced no developmental defects to the fetus.</p>
<p>A pre- and post-natal developmental study was performed in which pregnant cynomolgus monkeys were treated with golimumab during the second and third trimesters, and during lactation at doses up to 50 mg/kg twice weekly (33 times and 12 times greater than the maximal steady state human blood levels for maternal animals and neonates, respectively) and has revealed no evidence of harm to maternal animals or neonates. Golimumab was present in the neonatal serum from the time of birth and for up to six months postpartum. Exposure to golimumab during gestation and during the postnatal period caused no developmental defects in the infants.</p>
<p>IgG antibodies are known to cross the placenta during pregnancy and have been detected in the serum of infants born to patients treated with these antibodies. Since SIMPONI ARIA is an IgG antibody, infants born to women treated with SIMPONI ARIA during their pregnancy may be at increased risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> for up to 6 months. Administration of live vaccines to infants exposed to SIMPONI ARIA <span class="Italics">in utero</span> is not recommended for 6 months following the mother's last SIMPONI ARIA infusion during pregnancy <span class="Italics">[see <a href="#S5.10">Warnings and Precautions (5.10)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether SIMPONI ARIA is excreted in human milk or absorbed systemically after ingestion. Because many drugs and immunoglobulins are excreted in human milk, and because of the potential for adverse reactions in nursing infants from SIMPONI ARIA, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
<p>In the pre- and post-natal development study in cynomolgus monkeys in which golimumab was administered subcutaneously during pregnancy and lactation, golimumab was detected in the breast milk at concentrations that were approximately 400-fold lower than the maternal serum concentrations.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of SIMPONI ARIA in pediatric patients less than 18 years of age have not been established. Malignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with other TNF-blocking agents <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">In Trial 1 in RA, the number of patients ages 65 or older was too small to make comparisons with younger SIMPONI ARIA -treated patients. Because there is a higher incidence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in the geriatric population in general, caution should be used in treating geriatric patients with SIMPONI ARIA.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">In a clinical study, 5 patients received single infusions of up to 1000 mg of SIMPONI ARIA without serious adverse reactions or other significant reactions.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">SIMPONI ARIA (golimumab) is a human IgG1қ monoclonal antibody specific for human <span class="product-label-link" type="condition" conceptid="4147451" conceptname="Tumor necrosis">tumor necrosis</span> factor alpha (TNFα) that exhibits multiple glycoforms with molecular <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">masses</span> of approximately 150 to 151 kilodaltons. SIMPONI ARIA was created using genetically engineered mice immunized with human TNF, resulting in an antibody with human-derived antibody variable and constant regions. SIMPONI ARIA is produced by a recombinant cell line cultured by continuous perfusion and is purified by a series of steps that includes measures to inactivate and remove viruses.</p>
<p>The SIMPONI ARIA drug product is a sterile concentrated solution of the golimumab antibody supplied in a 4 mL glass vial for intravenous infusion.</p>
<p>SIMPONI ARIA does not contain preservatives, natural rubber or latex. The solution is colorless to light yellow with a pH of approximately 5.5. Each 4 mL vial of SIMPONI ARIA contains 50 mg golimumab, 9.5 mM L-histidine, 4.5% (w/v) sorbitol, and 0.015% (w/v) polysorbate 80.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Golimumab is a human monoclonal antibody that binds to both the soluble and transmembrane bioactive forms of human TNFα. This interaction prevents the binding of TNFα to its receptors, thereby inhibiting the biological activity of TNFα (a cytokine protein). There was no evidence of the golimumab antibody binding to other TNF superfamily ligands; in particular, the golimumab antibody did not bind or neutralize human lymphotoxin. Golimumab did not lyse human monocytes expressing transmembrane TNF in the presence of complement or effector cells.</p>
<p>Elevated TNFα levels in the blood, synovium, and joints have been implicated in the pathophysiology of <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>. TNFα is an important mediator of the articular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> that is characteristic of RA. Golimumab modulated the <span class="Italics">in vitro</span> biological effects mediated by TNF in several bioassays, including the expression of <span class="product-label-link" type="condition" conceptid="4175338" conceptname="Adhesion">adhesion</span> proteins responsible for leukocyte infiltration (E-selectin, ICAM-1 and VCAM-1) and the secretion of proinflammatory cytokines (IL-6, IL-8, G-CSF and GM-CSF).  The clinical relevance of these findings is unknown.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Following treatment with SIMPONI ARIA in patients with RA, decreases from baseline were observed in tissue inhibitor of metalloproteinases 1 (TIMP-1), matrix metalloproteinase-1 (MMP-1), matrix metalloproteinase-3 (MMP-3), resistin, <span class="product-label-link" type="condition" conceptid="4150054" conceptname="Interleukin-6">interleukin-6</span> (IL-6), macrophage inflammatory protein-1 (MIP-1b), vascular endothelial growth factor (VEGF), serum amyloid A (SAA), S100A12, and high sensitivity C-Reactive protein (hsCRP). Conversely, increases from baseline were observed in tartrate-resistant acid phosphatase (TRAP-5b). The clinical relevance of this information is not known.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Bold">Absorption</span></p>
<p>Following a single intravenous administration of 2 mg/kg SIMPONI ARIA, a mean C<span class="Sub">max</span> of 44.4 ±11.3 µg/mL was observed in patients with RA. Data directly comparing 2 mg/kg intravenous administration and 50 mg subcutaneous administration are not available.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Bold">Distribution</span></p>
<p>Following a single intravenous administration of 2 mg/kg SIMPONI ARIA, the mean volume of distribution was estimated to be 115 ± 19 mL/kg in healthy subjects, and 151 ± 61 mL/kg in patients with RA. The volume of distribution of golimumab may indicate that golimumab is distributed primarily in the circulatory system with limited extravascular distribution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Bold">Elimination</span></p>
<p>The elimination pathways for golimumab have not been characterized.</p>
<p>Following a single intravenous administration of 2 mg/kg SIMPONI ARIA, the systemic clearance of golimumab was estimated to be 6.9 ± 2.0 mL/day/kg in healthy subjects and 7.6 ± 2.0 mL/day/kg in patients with RA. The mean terminal half-life was estimated to be 12 ± 3 days in healthy subjects and the mean terminal half-life in RA patients was 14 ± 4 days.</p>
<p>When 2 mg/kg SIMPONI ARIA was administered intravenously to patients with RA at weeks 0, 4 and every 8 weeks thereafter, serum concentrations reached steady state by Week 12. Following IV administration, concomitant administration of methotrexate decreases the clearance of SIMPONI ARIA by approximately 9% based on population PK analysis. In addition, concomitant administration of methotrexate decreases the SIMPONI ARIA clearance by reducing the development of anti-golimumab antibodies. With concomitant use of MTX, treatment with 2 mg/kg golimumab every 8 weeks resulted in a mean steady-state trough serum concentration of approximately 0.4 ± 0.4 µg/mL in patients with active RA despite MTX therapy.</p>
<p>Population PK analysis indicated that concomitant use of NSAIDs, oral corticosteroids or sulfasalazine did not influence the apparent clearance of SIMPONI following SC administration.</p>
<p>Patients who developed anti-golimumab antibodies generally had low trough steady-state serum concentrations of golimumab.</p>
<p>No formal study of the effect of renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the PK of golimumab was conducted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Bold">Linearity</span></p>
<p>Golimumab exhibited approximately dose-proportional pharmacokinetics in patients with RA over the dose range of 0.1 to 10.0 mg/kg following a single intravenous dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Bold">Effect of weight on pharmacokinetics</span></p>
<p>Following intravenous administration, patients with higher body weight tended to have higher serum golimumab concentrations than patients with lower body weights when golimumab was administered on a mg/kg (body weight) basis. However, based on population PK analysis, there were no clinically relevant differences in golimumab exposure following intravenous administration of 2 mg/kg SIMPONI ARIA in patients across a range of different body weights.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13	NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term animal studies of golimumab have not been conducted to evaluate its carcinogenic potential. Mutagenicity studies have not been conducted with golimumab. A fertility study conducted in mice using an analogous anti-mouse TNFα antibody administered by the intravenous route at doses up to 40 mg/kg once per week showed no impairment of fertility.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The efficacy and safety of SIMPONI ARIA were evaluated in one multicenter, randomized, double-blind, controlled trial (Trial 1) in 592 patients ≥ 18 years of age with moderately to severely active RA despite concurrent MTX therapy and had not previously been treated with a biologic TNF-blocker. Patients were diagnosed according to the American College of Rheumatology (ACR) criteria, at least 3 months prior to administration of study agent and were required to have at least 6 swollen and 6 tender joints. Patients were randomized to receive either SIMPONI ARIA 2 mg/kg (n=395) or placebo (n=197) over a 30 minute intravenous infusion at Weeks 0, 4 and every 8 weeks thereafter in addition to their weekly maintenance MTX dose (15–25 mg). All patients receiving placebo + MTX received SIMPONI ARIA + MTX after Week 24, but the trial remained blinded until all patients had completed 108 weeks of treatment. Efficacy data were collected and analyzed through Week 52. Patients were allowed to continue stable doses of concomitant low dose corticosteroids (equivalent to ≤ 10 mg of prednisone a day) and/or NSAIDs. The use of other DMARDs including cytotoxic agents or other biologics was prohibited.</p>
<p>The primary endpoint in Trial 1 was the percentage of patients achieving an ACR 20 response at Week 14.   In Trial 1, the majority of subjects were women (82%) and were Caucasian (80%) with a median age of 52 years and a median weight of 70 kg. Median disease duration was 4.7 years, and 50% of the patients used at least one DMARD other than MTX in the past. At baseline, 81% of patients received concomitant NSAIDs and 81% of patients received low dose corticosteroids (equivalent to ≤ 10 mg of prednisone a day). The median baseline DAS28-CRP was 5.9 and the median van der Heijde-Sharp score at baseline was 28.5.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<p class="First"><span class="Bold Italics">Clinical Response</span></p>
<p>A greater percentage of patients treated with the combination of SIMPONI ARIA + MTX achieved ACR 20 at Week 14 and ACR50 at Week 24 versus patients treated with the placebo + MTX as shown in Table 2. The percent of patients achieving ACR 20 responses by visit for Trial 1 is shown in Figure 1. </p>
<a name="table2"></a><table width="75%">
<caption><span>Table 2:	Trial 1 – Proportion of Patients with an ACR Response</span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="Botrule First"><th class="Lrule Rrule" align="center" colspan="4">Trial 1 <br> Active RA, despite MTX </th></tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" valign="middle">Placebo + MTX</th>
<th class="Rrule" align="center" valign="middle">SIMPONI ARIA + MTX</th>
<th class="Rrule" align="center" valign="middle">95% CI<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>For difference in proportions</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>N reflects randomized patients.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">N<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td class="Rrule" align="center">197</td>
<td class="Rrule" align="center">395</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">ACR 20</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Week 14</td>
<td class="Rrule" align="center">25%</td>
<td class="Rrule" align="center">59%</td>
<td class="Rrule" align="center">25.9, 41.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Week 24</td>
<td class="Rrule" align="center">32%</td>
<td class="Rrule" align="center">63%</td>
<td class="Rrule" align="center">23.3, 39.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">ACR 50</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Week 14</td>
<td class="Rrule" align="center">9%</td>
<td class="Rrule" align="center">30%</td>
<td class="Rrule" align="center">15.3, 27.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Week 24	</td>
<td class="Rrule" align="center">13%</td>
<td class="Rrule" align="center">35%</td>
<td class="Rrule" align="center">15.1, 28.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">ACR 70</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Week 14</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">12%</td>
<td class="Rrule" align="center">5.3, 13.4</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left">Week 24</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">18%</td>
<td class="Rrule" align="center">8.8, 18.1</td>
</tr>
</tbody>
</table>
<table class="Noautorules" width="100%">
<caption><span>Figure 1:        Trial 1 – Percent of Patients Achieving ACR 20 Response Over Time: Randomized Patients</span></caption>
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="80%">
<col align="center" valign="top" width="10%">
<tbody class="Headless">
<tr>
<td align="center"></td>
<td align="center"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9e260a47-55af-4c92-8d88-a86ccc767fff&amp;name=simponi-01.jpg"></td>
<td align="center"></td>
</tr>
<tr>
<td align="center"></td>
<td align="center">The analysis is based on the intent-to-treat population. Last observation carried forward was performed for missing data.  Patients who discontinued treatment due to lack of efficacy were counted as non-responders, as were patients who started  prohibited medication or  failed to  achieve at least a 10% improvement in joint counts at Week 16.</td>
<td align="center"></td>
</tr>
</tbody>
</table>
<p>The improvement in all components of the ACR response criteria for the SIMPONI ARIA + MTX group was greater compared to the placebo + MTX group in Trial 1 as shown in Table 3.</p>
<a name="table3"></a><table width="75%">
<caption><span>Table 3:	Trial 1 – Components of ACR Response at Week 14 </span></caption>
<col align="left" valign="middle" width="20%">
<col align="center" valign="top" width="40%">
<col align="center" valign="top" width="40%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="2">Trial 1 <br>Active RA, despite MTX</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">Placebo + MTX</th>
<th class="Rrule" align="center">SIMPONI ARIA + MTX</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="3">Note: All values are means. </td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>N reflects randomized patients; actual number of patients evaluable for each endpoint may vary.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">N<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>
</td>
<td class="Rrule" align="center">197</td>
<td class="Rrule" align="center">395</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">Number of <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">swollen joints</span> (0–66) </span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Baseline</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">15</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Week 14</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">6</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">Number of tender joints (0–68) </span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Baseline</td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">26</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Week 14</td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">13</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">Patient's assessment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (0–10) </span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Baseline</td>
<td class="Rrule" align="center">6.5</td>
<td class="Rrule" align="center">6.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Week 14</td>
<td class="Rrule" align="center">5.6</td>
<td class="Rrule" align="center">3.9</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">Patient's global assessment of disease activity (0–10) </span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Baseline</td>
<td class="Rrule" align="center">6.5</td>
<td class="Rrule" align="center">6.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Week 14</td>
<td class="Rrule" align="center">5.5</td>
<td class="Rrule" align="center">4.0</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">Physician's global assessment of disease activity (0–10) </span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Baseline</td>
<td class="Rrule" align="center">6.3</td>
<td class="Rrule" align="center">6.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Week 14</td>
<td class="Rrule" align="center">4.9</td>
<td class="Rrule" align="center">3.1</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">HAQ score (0–3) </span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Baseline</td>
<td class="Rrule" align="center">1.6</td>
<td class="Rrule" align="center">1.6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Week 14</td>
<td class="Rrule" align="center">1.4</td>
<td class="Rrule" align="center">1.1</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">CRP (mg/dL) (0–1)</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Baseline</td>
<td class="Rrule" align="center">2.2</td>
<td class="Rrule" align="center">2.8</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left">Week 14</td>
<td class="Rrule" align="center">1.8</td>
<td class="Rrule" align="center">0.9</td>
</tr>
</tbody>
</table>
<p>At Week 14, a greater proportion of patients treated with SIMPONI ARIA + MTX achieved a low level of disease activity as measured by a DAS28-CRP less than 2.6 compared with the placebo + MTX group (15% compared to 5%; 95% confidence interval for difference [6.3%,15.5%]).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2"></a><p></p>
<p class="First"><span class="Bold Italics">Radiographic Response</span></p>
<p>In Trial 1, structural joint damage was assessed radiographically and expressed as a change in van der Heijde-Modified Sharp Score (vdH-S) and its components, the erosion score and Joint Space Narrowing (JSN) score, at Week 24 compared to baseline. The SIMPONI ARIA + MTX treatment group inhibited the progression of structural damage compared with placebo + MTX, as assessed by total vdH-S score as shown in Table 4.</p>
<table width="75%">
<caption><span>Table 4:	Trial 1 – Radiographic Change From Baseline at Week 24</span></caption>
<col align="left" valign="middle" width="34%">
<col align="center" valign="middle" width="32%">
<col align="center" valign="middle" width="34%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" valign="top">Placebo + MTX <br> (N=197)<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a>
</th>
<th class="Rrule" align="center" valign="top">SIMPONI ARIA + MTX <br> (N=395)<a href="#footnote-4" class="Sup">*</a><span class="Sup">,</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a>
</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">Mean</th>
<th class="Rrule" align="center">Mean</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>N reflects randomized patients</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>p-value is displayed only for the major secondary endpoint</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">‡</a></dt>
<dd>p≤0.001</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Change Total vdH-S Score</span></td>
<td class="Rrule" align="center">1.1</td>
<td class="Rrule" align="center">0.03<a name="footnote-reference-6" href="#footnote-6" class="Sup">‡</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Change Erosion Score</span></td>
<td class="Rrule" align="center">0.5</td>
<td class="Rrule" align="center">-0.1</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Bold">Change JSN Score</span></td>
<td class="Rrule" align="center">0.6</td>
<td class="Rrule" align="center">0.1</td>
</tr>
</tbody>
</table>
<p>At Week 24, a greater proportion of patients in the SIMPONI ARIA + MTX group (71%) had no progression of structural damage (change in the total vdH-S score ≤ 0), compared to 57% of patients in the placebo + MTX group. At Week 52, the mean change from baseline in total vdH-S score was 1.2 in patients originally randomized to placebo + MTX who crossed over to SIMPONI ARIA + MTX at Week 16 or 24, and 0.1 in patients originally randomized to SIMPONI ARIA + MTX who remained on active treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.3"></a><p></p>
<p class="First"><span class="Bold Italics">Physical Function Response in Patients with RA</span></p>
<p>Physical function was assessed by the <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> index of the Health Assessment Questionnaire (HAQ-DI). At Week 14, the SIMPONI ARIA + MTX group showed greater mean improvement in the HAQ-DI compared with placebo + MTX (0.5 compared to 0.2; 95% confidence interval for difference [0.2, 0.4]).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.4"></a><p></p>
<p class="First"><span class="Bold Italics">Other Health-Related Outcomes</span></p>
<p>General health status was assessed by the 36-item Short Form Health Survey (SF-36). In Trial 1, patients receiving SIMPONI ARIA + MTX demonstrated greater improvement from baseline compared with placebo + MTX in physical component summary (PCS), mental component summary (MCS) scores and in all 8 domains of the SF-36.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">SIMPONI ARIA is available in packs of 1 vial NDC 57894-350-01</p>
<p><span class="Bold">Vial</span></p>
<p>Each single-use vial contains 50 mg of SIMPONI ARIA per 4 mL of solution.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">Storage and Stability</span></p>
<p>SIMPONI ARIA must be refrigerated at 2ºC to 8ºC (36ºF to 46ºF) and protected from light. Keep the product in the original carton to protect from light until the time of use. Do not freeze. Do not shake. Do not use SIMPONI ARIA beyond the expiration date (EXP) on the vial label.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See <a href="#med_guide">FDA-approved patient labeling (Medication Guide)</a></p>
<p>Advise patients of the potential benefits and risks of SIMPONI ARIA. Instruct patients to read the Medication Guide before starting SIMPONI ARIA therapy and to read it each time the prescription is renewed.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></p>
<p>Inform patients that SIMPONI ARIA may lower the ability of their immune system to fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Instruct the patient of the importance of contacting their doctor if they develop any symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>, invasive <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>, and <span class="product-label-link" type="condition" conceptid="4281232" conceptname="Type B viral hepatitis">hepatitis B reactivation</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.2"></a><p></p>
<p class="First"><span class="Bold Italics">Malignancies</span></p>
<p>Patients should be counseled about the risk of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> and other malignancies while receiving SIMPONI ARIA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.3"></a><p></p>
<p class="First"><span class="Bold Italics">Other Medical Conditions</span></p>
<p>Advise patients to report any signs of new or worsening medical conditions such as <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, demyelinating disorders, autoimmune diseases, liver disease, <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span>, or <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">Manufactured by: <br> Janssen Biotech, Inc. <br> Horsham, PA 19044 <br> US License No. 1864 at <br> Cilag AG <br> Schaffhausen, Switzerland</p>
<p>© Janssen Biotech, Inc. 2013</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="med_guide"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">MEDICATION GUIDE</span></p>
<p><span class="Bold">SIMPONI ARIA<span class="Sup">®</span></span><br><span class="Bold">(</span>SIM-puh-nee AHR-ee-uh<span class="Bold">) <br> (golimumab) <br> For Infusion</span></p>
<p>Read the Medication Guide for SIMPONI ARIA before each infusion. There may be new information. This Medication Guide does not take the place of talking with your doctor about your medical condition or treatment.  It is important to remain under your doctor's care while receiving SIMPONI ARIA.</p>
<p><a name="most_important"></a><span class="Bold">What is the most important information I should know about SIMPONI ARIA?</span></p>
<p>SIMPONI ARIA is a medicine that affects your immune system. SIMPONI ARIA can lower the ability of your immune system to fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Some people have serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> while taking SIMPONI ARIA, including <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> (TB), and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by bacteria, fungi, or viruses that spread throughout their body. Some people have died from these serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<ul>
<li>Your doctor should test you for TB and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B before starting SIMPONI ARIA.</li>
<li>Your doctor should monitor you closely for signs and symptoms of TB during treatment with SIMPONI ARIA.</li>
</ul>
<p>You should not receive SIMPONI ARIA if you have any kind of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> unless your doctor says it is okay.</p>
<p><span class="Bold">Before receiving SIMPONI ARIA, tell your doctor if you:</span></p>
<ul class="Disc">
<li>think you have an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or have symptoms of an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> such as: 								<table class="Noautorules" width="100%">
<col align="left" valign="top" width="10%">
<col align="left" valign="top" width="35%">
<col align="left" valign="top" width="55%">
<tbody class="Headless"><tr>
<td align="left"> </td>
<td align="left"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, sweat, or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></li>
<li><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span></li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span></li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></li>
<li>blood in <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">phlegm</span></li>
<li><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span></li>
</ul></td>
<td align="left"><ul class="Circle">
<li>warm, red, or painful skin or sores on your body</li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li>burning when you urinate or urinate more often than normal</li>
<li>feel very tired</li>
</ul></td>
</tr></tbody>
</table>
</li>
<li>are being treated for an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</li>
<li>get a lot of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or have <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that keep coming back.</li>
<li>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, HIV, or a weak immune system.  People with these conditions have a higher chance for <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</li>
<li>have TB, or have been in close contact with someone with TB.</li>
<li>live, have lived, or traveled to certain parts of the country (such as the Ohio and Mississippi River valleys and the Southwest) where there is an increased chance for getting certain kinds of <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> (<span class="product-label-link" type="condition" conceptid="433134" conceptname="Histoplasmosis">histoplasmosis</span>, <span class="product-label-link" type="condition" conceptid="437217" conceptname="Coccidioidomycosis">coccidioidomycosis</span>, <span class="product-label-link" type="condition" conceptid="433146" conceptname="Blastomycosis">blastomycosis</span>). These <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may happen or become more severe if you receive SIMPONI ARIA. Ask your doctor if you do not know if you have lived in an area where these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> are common.</li>
<li>have or have had <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B.</li>
<li>use the medicine ORENCIA (abatacept), KINERET (anakinra), ACTEMRA (tocilizumab) or RITUXAN (rituximab).</li>
</ul>
<p><span class="Bold">After receiving SIMPONI ARIA</span>, call your doctor right away if you have any symptoms of an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. SIMPONI ARIA can make you more likely to get <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or make worse any <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> that you have.</p>
<p><span class="Bold">Cancer</span></p>
<ul>
<li>For children and adults receiving TNF-blocker medicines, including SIMPONI ARIA, the chances of getting cancer may increase.</li>
<li>There have been cases of unusual cancers in children and teenage patients taking TNF-blocking agents.</li>
<li>People with inflammatory diseases including <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> especially those with very active disease, may be more likely to get <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>.</li>
<li>Some people receiving medicines that are like SIMPONI ARIA, called TNF-blockers developed a rare type of cancer called hepatosplenic T-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>. This type of cancer often results in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Most of these people were male teenagers or young men. Also, most people were being treated for Crohn's disease or <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> with a TNF-blocker and another medicine called azathioprine or 6-mercaptopurine.</li>
<li>Some people treated with SIMPONI ARIA developed skin cancer. If any changes in the appearance of your skin or growths on your skin occur during or after your treatment with SIMPONI ARIA, tell your doctor.</li>
<li>You should see your doctor periodically for skin examinations, especially if you have a history of skin cancer.</li>
</ul>
<p><span class="Bold">What is SIMPONI ARIA?</span></p>
<p>SIMPONI ARIA is a prescription medicine called a <span class="product-label-link" type="condition" conceptid="4147451" conceptname="Tumor necrosis">Tumor Necrosis</span> Factor (TNF) blocker. SIMPONI ARIA is used with the medicine methotrexate to treat adults with moderately to severely active <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> (RA).</p>
<p>SIMPONI ARIA is not for children under 18 years of age.</p>
<p><span class="Bold">What should I tell my doctor before starting treatment with SIMPONI ARIA?</span></p>
<p>SIMPONI ARIA may not be right for you. Before receiving SIMPONI ARIA, tell your doctor about all your medical conditions, including if you:</p>
<ul>
<li>have an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (see "<a href="#most_important">What is the most important information I should know about SIMPONI ARIA?</a>")</li>
<li>have or have had <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> or any other type of cancer.</li>
<li>have or had <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span></li>
<li>have or have had a condition that affects your nervous system, such as <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> or Guillain-Barré syndrome</li>
<li>have a skin problem called <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span></li>
<li>have recently received or are scheduled to receive a vaccine. People receiving SIMPONI ARIA should not receive live vaccines or treatment with a weakened bacteria (such as BCG for <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>). People receiving SIMPONI ARIA can receive non-live vaccines.</li>
<li>have a baby and you received SIMPONI ARIA during your pregnancy. Tell your baby's doctor before your baby receives any vaccine. Your baby may have an increased chance of getting an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> for up to 6 months after birth.</li>
<li>are pregnant or planning to become pregnant. It is not known if SIMPONI ARIA will harm your unborn baby.</li>
<li>are breastfeeding. It is not known if SIMPONI ARIA passes into your breast milk. You and your doctor should decide if you will receive SIMPONI ARIA or breastfeed. You should not do both without talking to your doctor first.</li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take</span>, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p>
<p>Especially tell your doctor if you:</p>
<ul>
<li>use ORENCIA (abatacept) or KINERET (anakinra). You should not receive SIMPONI ARIA while you are also taking ORENCIA (abatacept) or KINERET (anakinra).</li>
<li>use other TNF-blocker medicines, including REMICADE (infliximab), HUMIRA (adalimumab), ENBREL (etanercept), or CIMZIA (certolizumab pegol).</li>
<li>receive RITUXAN (rituximab) or ACTEMRA (tocilizumab).</li>
</ul>
<p>Ask your doctor if you are not sure if your medicine is one listed above.</p>
<p>Keep a list of all your medications with you to show your doctor and pharmacist each time you get a new medicine.</p>
<p><span class="Bold">How should I receive SIMPONI ARIA?</span></p>
<ul>
<li> SIMPONI ARIA is prepared and given by a healthcare provider through a needle placed in your vein (infusion). The infusion is usually given in your arm and should take 30 minutes.</li>
<li> Your doctor will decide how much SIMPONI ARIA you will receive based on your weight. Your usual schedule for receiving SIMPONI ARIA after your first treatment should be: 						<ul class="Circle">
<li>4 weeks after your first treatment</li>
<li>every 8 weeks after that</li>
</ul>
</li>
<li>If you forget or miss an appointment to receive SIMPONI ARIA, make another appointment as soon as possible.</li>
<li>You may continue to use other medicines for your treatment while taking SIMPONI ARIA, such as non-steroidal anti-inflammatory drugs (NSAIDs), prescription steroids, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief medicines.</li>
</ul>
<p><span class="Bold">What are the possible side effects of SIMPONI ARIA?</span></p>
<p><span class="Bold">SIMPONI ARIA can cause serious side effects, including:</span></p>
<ul>
<li>See "<span class="Bold"><a href="#most_important">What is the most important information I should know about SIMPONI ARIA?</a>"</span>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in people who carry the virus in their blood</span>. If you are a carrier of the <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (a virus that affects the liver), the virus can become active while you receive SIMPONI ARIA. Your doctor should do blood tests before you start treatment with SIMPONI ARIA and while you are receiving SIMPONI ARIA. Tell your doctor if you have any of the following symptoms of a possible <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>: 								<table class="Noautorules" width="100%">
<col align="left" valign="top" width="10%">
<col align="left" valign="top" width="35%">
<col align="left" valign="top" width="55%">
<tbody class="Headless"><tr>
<td align="left"> </td>
<td align="left"><ul class="Circle">
<li>feel very tired</li>
<li>clay-colored bowel movements</li>
<li>dark urine</li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fevers</span></li>
<li>skin or eyes look yellow</li>
</ul></td>
<td align="left"><ul class="Circle">
<li>little or no appetite</li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span></li>
<li><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></li>
<li><span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach discomfort</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span></li>
</ul></td>
</tr></tbody>
</table>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span>, including new <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or worsening of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> that you already have.</span> New or worse <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> can happen in people who use TNF-blocker medicines including SIMPONI ARIA. <ul class="Circle">
<li>If you have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, your condition should be watched closely while you receive SIMPONI ARIA.</li>
<li>Call your doctor right away if you get new or worsening symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> while receiving SIMPONI ARIA (such as <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your lower legs or feet, or sudden <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>).</li>
</ul>
</li>
<li>
<p class="First"><span class="Bold">Nervous System Problems </span></p>
<p>Rarely, people using TNF-blocker medicines, including SIMPONI ARIA, have nervous system problems such as <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> or Guillain-Barré syndrome.</p>
<p>Tell your doctor right away if you get any of these symptoms:</p>
<ul class="Circle">
<li>vision changes</li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in your arms or legs</li>
<li><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> in any part of your body</li>
</ul>
</li>
<li>
<p class="First"><span class="Bold">Liver Problems</span></p>
<p>Liver problems can happen in people who use TNF-blocker medicines, including SIMPONI ARIA. These problems can lead to <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Call your doctor right away if you have any of these symptoms:</p>
<ul class="Circle">
<li>feel very tired</li>
<li>skin or eyes look yellow</li>
<li>poor appetite or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> on the right side of your stomach (abdomen)</li>
</ul>
</li>
<li>
<p class="First"><span class="Bold">Blood Problems </span></p>
<p>Low blood counts have been seen with TNF-blockers, including SIMPONI ARIA. Your body may not make enough blood cells that help fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or help stop <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Symptoms include <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> easily, or looking <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span>. Your doctor will check your blood counts before and during treatment with SIMPONI ARIA.</p>
</li>
<li>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> can happen in people who use TNF-blocker medicines including SIMPONI ARIA. Some reactions may be serious and can be life threatening. Some of these reactions can happen after receiving your first dose of SIMPONI ARIA. Call your doctor right away if you have any of these symptoms of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>:</p>
<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span></li>
<li>swollen face</li>
<li>breathing trouble</li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></li>
</ul>
</li>
</ul>
<p><span class="Bold">The most common side effects of SIMPONI ARIA include: </span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span> (<span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, and <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span> or <span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> such as flu and <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> in the mouth</li>
<li><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span></li>
<li>high blood pressure</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
</ul>
<p>Other side effects with SIMPONI ARIA include:</p>
<ul class="Disc"><li>
<span class="Bold">Immune System Problems. </span>Rarely, people using TNF-blocker medicines have developed symptoms that are like the symptoms of Lupus. Tell your doctor if you have any of these symptoms: <ul class="Circle">
<li>a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> on your cheeks or other parts of the body</li>
<li>sensitivity to the sun</li>
<li>new joint or <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span></li>
<li>becoming very tired</li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the feet, ankles, or legs</li>
</ul>
</li></ul>
<p>These are not all of the side effects with SIMPONI ARIA. Tell your doctor about any side effect that bothers you or does not go away.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">General Information about SIMPONI ARIA</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in the Medication Guide. Do not use SIMPONI ARIA for a condition for which it was not prescribed.</p>
<p>This Medication Guide summarizes the most important information about SIMPONI ARIA. If you would like more information, talk to your doctor. You can ask your doctor or pharmacist for information about SIMPONI ARIA that is written for health professionals.</p>
<p>For more information go to www.SimponiAria.com or call 1-800-JANSSEN (1-800-526-7736).</p>
<p><span class="Bold">What are the ingredients in SIMPONI ARIA? </span></p>
<p>Active ingredient: golimumab</p>
<p>Inactive ingredients: L-histidine, polysorbate 80, and sorbitol. SIMPONI ARIA does not contain preservatives, natural rubber or latex.</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>Manufactured by: <br> Janssen Biotech, Inc. <br> Horsham, PA 19044 <br> US License No. 1864 at <br> Cilag AG <br> Schaffhausen, Switzerland</p>
<p>© Janssen Biotech, Inc. 2013</p>
<p>Approved: August 2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 4 mL Vial Carton</span></p>
<p><span class="Bold">NDC 57894-350-01</span></p>
<p><span class="Bold">Simponi ARIA</span><span class="Sup">®</span><br> golimumab </p>
<p><span class="Bold">50 mg/4 mL</span></p>
<p>(12.5 mg/mL)</p>
<p><span class="Bold">For intravenous infusion</span></p>
<p>Single-use vial. <br> Discard unused portion.</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Provide the enclosed Medication Guide <br> to each patient.</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 4 mL Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9e260a47-55af-4c92-8d88-a86ccc767fff&amp;name=simponi-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SIMPONI ARIA 		
					</strong><br><span class="contentTableReg">golimumab solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:57894-350</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>golimumab</strong> (golimumab) </td>
<td class="formItem">golimumab</td>
<td class="formItem">50 mg  in 4 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sorbitol</strong></td>
<td class="formItem">180 mg  in 4 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>histidine monohydrochloride monohydrate</strong></td>
<td class="formItem">6.42 mg  in 4 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>histidine</strong></td>
<td class="formItem">1.14 mg  in 4 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem">0.6 mg  in 4 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:57894-350-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">4 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:57894-350-89</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">4 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125433</td>
<td class="formItem">07/19/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Janssen Biotech, Inc.
							(099091753)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cilag AG</td>
<td class="formItem"></td>
<td class="formItem">483237103</td>
<td class="formItem">MANUFACTURE(57894-350), ANALYSIS(57894-350), LABEL(57894-350), PACK(57894-350)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Janssen Biologics</td>
<td class="formItem"></td>
<td class="formItem">987061921</td>
<td class="formItem">API MANUFACTURE(57894-350), ANALYSIS(57894-350)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Janssen Biologics, B.V.</td>
<td class="formItem"></td>
<td class="formItem">409612918</td>
<td class="formItem">API MANUFACTURE(57894-350), ANALYSIS(57894-350)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Anderson Brecon</td>
<td class="formItem"></td>
<td class="formItem">053217022</td>
<td class="formItem">LABEL(57894-350), PACK(57894-350)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6fdfeacc-c5cd-41d7-aab0-fbcfc87c5e68</div>
<div>Set id: 9e260a47-55af-4c92-8d88-a86ccc767fff</div>
<div>Version: 6</div>
<div>Effective Time: 20150810</div>
</div>
</div> <div class="DistributorName">Janssen Biotech, Inc.</div></p>
</body></html>
